|Image for illustration only|
A new form of drug drastically improves survival rates of younger women with the most common type of breast cancer, researchers said on Saturday (Jun 1), citing the results of an international clinical trial.
The findings, presented at the annual meeting of the American Society of Clinical Oncology in Chicago, showed that the addition of cell-cycle inhibitor ribociclib increased survival rates to 70% after three and a half years.
The drug works by inhibiting the activity of cancer-cell promoting enzymes.
The treatment is less toxic than traditional chemotherapy because it more selectively targets cancerous cells, blocking their ability to multiply.
Read more @ https://www.channelnewsasia.com/news/world/new-breast-cancer-drug-found-to-boost-survival-rates-by-30-11588828